Nektar Reports on Advancements with Clinical Pipeline and Introduces New Preclinical Candidates at Investor and Analyst R&D Day
October 08, 2013 at 11:15 AM EDT
Nektar Therapeutics (Nasdaq: NKTR ) will present an overview of the company's proprietary drug candidate pipeline during the company's R&D Day for investors and analysts today from 11:30 a.m. to 4:30 p.m. ET in New York City. Pain management specialists will present data from two Phase 2 studies of
